Alnylam Pharmaceuticals Q3 2026 Results: Net Income $2.17B, Up 640.5% YoY
Alnylam Pharmaceuticals reported 133,937,576 shares of common stock outstanding as of October 23, 2026. The filing outlines the company's 'Alnylam 2030' strategy and highlights the commercial progress of its RNAi therapeutics, including AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO.
- Key figure
- Net income $2.17B · +640.5% YoY